Glenmark Pharmaceuticals recalled 44,328 bottles of Carvedilol Tablets, USP, 3.125 mg on August 7, 2025. The recall follows the discovery of N-Nitroso Carvedilol I impurity above acceptable levels. Consumers should stop using this medication immediately and consult their healthcare providers.
CGMP Deviations: Presence of a nitrosamine, N-Nitroso Carvedilol I Impurity above the current Acceptable Intake Level.
Consumers and healthcare providers should stop using this product immediately. Contact Glenmark Pharmaceuticals Inc., USA or your healthcare provider for guidance. Notification method: Letter
The recall includes Carvedilol Tablets in 500-count bottles (NDC 68462-162-05) and 100-count bottles (NDC 68462-162-01). These products were distributed nationwide in the USA and manufactured by Glenmark Pharmaceuticals Ltd in Goa, India.
The recall was issued due to CGMP deviations resulting in the presence of N-Nitroso Carvedilol I, a nitrosamine impurity. This impurity is above the current acceptable intake level, which poses potential health risks to consumers.
No specific injuries or incidents have been reported related to this recall. The FDA classified this recall as Class II, indicating a potential health hazard.
Consumers and healthcare providers should stop using the affected Carvedilol Tablets immediately. Contact Glenmark Pharmaceuticals Inc. or your healthcare provider for further guidance and to discuss possible alternatives.
For more information, consumers can call Glenmark Pharmaceuticals Inc. or visit their official website. The recall notification has also been sent via letter.
Glenmark Pharmaceuticals Inc. recalled 13,824 tubes of Azelaic Acid Gel on September 17, 2025. The recall stems from market complaints regarding a gritty texture. Consumers should stop using the product immediately and contact their healthcare provider.
Skin MD by Dr Monika Kiripolsky recalled its Body Acne Cleanser on September 12, 2025. The recall follows the discovery of elevated benzene levels in the product. This contamination poses a high health risk to consumers in California and Georgia.
Private Label Skin Care recalled its Micronized BPO Gel Cleanser 10% on September 12, 2025. Elevated benzene levels prompted the recall in California and Georgia. Consumers must stop using the product immediately and seek guidance from healthcare providers.